Dr. David Latshaw, Ph.D. - Co-Founder and CEO, BioPhy - Providing Practical AI For Drug Development

Dr. David Latshaw, Ph.D. is Co-Founder and CEO of BioPhy ( https://www.biophy.ai/ ), a Philadelphia based artificial intelligence company which has developed a set of platforms that provide quantitative metrics to drug company partners about what drugs and clinical trials will ultimately succeed. Dr. Latshaw is a computational biomolecular and chemical engineer by training and most recently led the deployment of more than 20 programs that leveraged AI across several drug development functions at Johnson & Johnson’s Advanced Technologies Center of Excellence. This impacted $16 billion in yearly sales, reducing costs by 20 percent, and a 50 percent increase in reliability. His work has been recognized by the World Economic Forum, McKinsey & Company, and the National Academy of Engineering. Dr. Latshaw has a BSE in Chemical Engineering from Arizona State University, a Ph.D. in Chemical and Biomolecular Engineering from North Carolina State University, and a Master of Business Administration - MBA, Finance and Operations, from The Wharton School.